Cytiva Delivers KUBio To Lonza
From site selection in Guangzhou Biopark to handover during the global pandemic, 17,000-square meter site was completed in less than two years
From Lonza’s first manufacturing site for biologics in China, the healthcare leader will provide services and manufacturing needed to respond to growing global pharmaceutical needs
Site to become a strategic base in China for Lonza to provide CDMO services throughout Asia Pacific region
Cytiva, a global life sciences leader, has successfully completed another KUBio installation, this time to global healthcare solutions provider Lonza, in Guangzhou Biopark, China. The high throughput modular biomanufacturing facility will offer process development and manufacturing for Chinese companies developing innovative medicines, as well as multinationals with manufacturing requirements in China.
/PRNewswire/ Cytiva, a global life sciences leader, has successfully completed another KUBio installation, this time to global healthcare solutions provider.